Troxerutin to prevent blood clots in COVID-19 patients
Part of Blood & lymphatic, Infections clinical trials.
This trial tests if the drug troxerutin can prevent dangerous blood clots in adults hospitalized with mild or severe COVID-19. If you have COVID-19 and are not already on blood thinners or at high risk for bleeding, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have tested positive for COVID-19 (PCR test).
- You have mild symptoms (like fever, cough, tiredness) or severe symptoms (like trouble breathing or low oxygen levels).
- You are not pregnant, breastfeeding, or within 6 weeks after giving birth.
- You do not have a bleeding disorder, active ulcers, or recent surgery (within 15 days).
- You are not already on a blood thinner called heparin for a medical need.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ratutrelvir, for people with mild to moderate COVID-19. It aims to find a safe and effective dose to help you feel better faster.
This trial tests if a new medicine called ibuzatrelvir can help people with COVID-19 who have certain health risks avoid severe illness. It is for patients who cannot or choose not to take another COVID-19 pill called Paxlovid.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial tests defibrotide to see if it improves outcomes in people hospitalized with severe COVID-19. You may be considered if you have confirmed infection, abnormal chest imaging, and meet specific severity and safety requirements.
This trial tests a new antiviral pill, secutrelvir, for people with mild to moderate covid-19 who are at higher risk of getting seriously ill. It aims to see if the drug can prevent hospitalization or severe disease.
This study looks at blood clot–related complications after COVID-19 (and in some cases flu) in adults admitted to the hospital. It may help doctors better understand and manage these complications.
Hear when a new COVID 19 Associated Coagulopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.